EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/ Levo ‐Leucovorin for Pancreatic Cancer

Akane Wakabayashi iD, Rei Tanaka iD, Yurie Fukumuro iD, Keita Mori iD, Junya Sato iD, Hiroshi Ishikawa iD, Michihiro Shino iD, Takeshi Kawakami iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Akane Wakabayashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Irinotecan, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil (5‐FU)/ levo ‐leucovorin ( Levo ‐LV) therapy is recommended as the standard of care for unresectable locally advanced (UR‐LA) and metastatic pancreatic cancer after failure of gemcitabine‐containing regimens. Although the concomitant administration of nal‐IRI and Levo ‐LV benefits from a reduced hospital stay, nal‐IRI is usually administered after Levo ‐LV owing to insufficient data on compatibility reactions. This study aimed to compare the safety and efficacy of the sequential and concomitant administration of nal‐IRI and Levo ‐LV.

Methods

Data of patients with UR‐LA or metastatic pancreatic cancer who received nal‐IRI plus 5‐FU/Levo‐LV between 2020 and 2023 at Shizuoka Cancer Center were retrospectively collected. Patients were classified into the sequential administration group (Group S) and concomitant administration group (Group C) to compare adverse events, infusion time, and survival. Univariate and multivariate analyses were performed to identify independent prognostic factors in each group.

Results

A total of 94 patients were included (44 in Group S and 50 in Group C). There was no significant difference in the incidence of Grade 3 or higher adverse events between the two groups. The median total infusion times for nal‐IRI plus 5‐FU/Levo‐LV in Groups S and C were 271 and 149 min, respectively ( p < 0.001). Overall survival estimates were 5.6 months (95% confidence interval [CI] 3.78–8.57) in Group S and 8.4 months (95% CI 6.77–10.3) in Group C (unstratified HR 0.65, 95% CI 0.42–1.02; p = 0.058). In the multivariate analysis for PFS and OS, the method of administration was not identified as an independent prognostic factor. Concomitant administration of Levo ‐LV with nal‐IRI may not increase adverse events or impact efficacy while reducing infusion time.

Conclusion

Concomitant administration of Levo ‐LV with nal‐IRI may not increase adverse events or impact efficacy compared to sequential administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsIrinotecanAntineoplastic Combined Chemotherapy ProtocolsHumansFluorouracilLeucovorinLiposomesFemaleRetrospective StudiesMaleAgedMiddle AgedNanoparticles

Stichwörter der Autor:innen

adverse eventsconcomitant administrationdrug compatibilitynanoliposomal irinotecanpancreas cancer

Substanzen

FluorouracilIrinotecanLeucovorinLiposomes

Autor:innen und Institutionen

  • Department of Pharmacy, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
  • Department of Pharmacy, Shonan University of Medical Sciences, Yokohama, Kanagawa, Japan.
  • Department of Nursing, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
  • Clinical Research Center, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.

ORCID-Profile: Akane Wakabayashi, Rei Tanaka, Yurie Fukumuro, Keita Mori, Junya Sato, Hiroshi Ishikawa, Michihiro Shino, Takeshi Kawakami

Zitieren

APA

Wakabayashi, A., Tanaka, R., Fukumuro, Y., Mori, K., Sato, J., Ishikawa, H., Shino, M., & Kawakami, T. (2026). Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/ Levo ‐Leucovorin for Pancreatic Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70485

Vancouver

Wakabayashi A, Tanaka R, Fukumuro Y, Mori K, Sato J, Ishikawa H, et al. Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/ Levo ‐Leucovorin for Pancreatic Cancer. Cancer Reports. 2026. doi:10.1002/cnr2.70485

BibTeX
@article{Wakabayashi2026,
  author = {Wakabayashi, Akane and Tanaka, Rei and Fukumuro, Yurie and Mori, Keita and Sato, Junya and Ishikawa, Hiroshi and Shino, Michihiro and Kawakami, Takeshi},
  title = {Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/ Levo ‐Leucovorin for Pancreatic Cancer},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70485}
}
Kostenlos starten →